December 20, 2023
2 min watch
Save
VIDEO: TRANSFORM-1, MANIFEST-2 studies probe combo therapies in myelofibrosis
In this video, Aaron T. Gerds, MD, MS, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.
Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute, discussed how the two studies unfolded – TRANSFORM-1 examined ruxolitinib plus navitoclax versus placebo, while MANIFEST-2 examined ruxolitinib plus pelabresib versus placebo.
“We are clearly moving as a field towards combination therapy for both frontline and relapse in refractory disease. So again, two incredibly important studies that are potentially practice changing,” Gerds said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Gerds reports serving in an advisory/consulting role for Bristol Myers Squibb, CTI Biopharma, GSK, Kartos/Telios, MorphoSys and PharmaEssentia.
Read more about